Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting
June 20, 2024 01:00 ET
|
Nykode Therapeutics ASA
OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy
June 11, 2024 01:00 ET
|
Nykode Therapeutics ASA
OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer
May 14, 2024 01:15 ET
|
Nykode Therapeutics ASA
OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics - Quarterly report Q1 2024
May 14, 2024 01:00 ET
|
Nykode Therapeutics ASA
OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
April 19, 2024 01:00 ET
|
Nykode Therapeutics ASA
OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
March 21, 2024 02:00 ET
|
Nykode Therapeutics ASA
Updated survival data from Phase 2 trial (C-02) in advanced cervical cancer affirm prolonged benefits and indicate a synergistic treatment effect of Nykode’s VB10.16 and atezolizumab (Tecentriq®).New...
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases
March 19, 2024 02:00 ET
|
Nykode Therapeutics ASA
OSLO, Norway, March 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics - Quarterly report Q3 2023
November 15, 2023 04:30 ET
|
Nykode Therapeutics ASA
OSLO, Norway, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston
October 09, 2023 00:45 ET
|
Nykode Therapeutics ASA
Nykode’s APC targeted vaccine technology can be delivered as mRNA and generate strong T cell responsesNykode’s APC targeted vaccine technology consistently results in faster, broader and stronger...
Nykode Therapeutics Announces Advances in Clinical Pipeline and Research
September 20, 2023 10:06 ET
|
Nykode Therapeutics ASA
On-track to leverage promising Phase 2 cervical cancer data with FDA clearance to start a potentially registrational trial in 2023, and expansion into head and neck, two areas with high unmet...